DelveInsight’s “Brain Cancer Market Insights, Epidemiology, and Market Forecast–2034” provides a comprehensive analysis of brain cancer, covering both historical and projected epidemiological trends, as well as current and future market dynamics across the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.
To Know in detail about the Brain Cancer market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Brain Cancer Market Forecast
Some of the key facts of the Brain Cancer Market Report:
The Brain Cancer market is projected to experience significant growth with a notable CAGR over the study period (2020–2034).
In 2023, the United States held the largest market share for brain cancer among the seven major markets (7MM). Within the EU4 and the UK, Italy is expected to generate the highest revenue share by 2034, followed by Germany. In terms of incident cases, the U.S. accounted for over 38% of total cases in the 7MM in 2023.
Regarding gender distribution, males were more frequently affected, representing approximately 60% of cases, while females accounted for around 40% in the U.S. High-grade brain tumors (Grades III and IV) were more common than low-grade tumors, comprising nearly 70% of cases. Brain tumors were most prevalent among individuals aged 40–64, followed by those 65 and older. In 2023, the U.S. reported roughly 23,000 new cases of primary brain tumors, with numbers expected to increase over the forecast period.
Several notable developments occurred in recent years:
-
December 2024: Kazia Therapeutics’ stock fell 26% to $2.28 after the FDA indicated it may only grant standard approval for paxalisib, a glioblastoma treatment, rather than accelerated approval. Earlier in the year, the stock had already dropped 48%, despite paxalisib showing improved overall survival in a July trial.
-
April 2024: The US FDA granted accelerated approval to Day One Biopharmaceuticals’ OJEMDA (tovorafenib) for patients aged 6 months and older with certain relapsed or refractory pediatric low-grade glioma.
-
April 2024: TME Pharma received Fast Track Designation from the FDA for NOX-A12 (olaptesed pegol), a CXCL12 inhibitor, in combination with radiotherapy and bevacizumab for glioblastoma.
-
February 2024: Servier announced FDA acceptance and priority review of the NDA for vorasidenib, which could become the first targeted therapy for patients with IDH-mutant gliomas. The PDUFA date is set for August 20, 2024.
Key Companies in the brain cancer market include Y-mAbs Therapeutics Inc., Shimadzu Corporation, Bristol-Myers Squibb, Bayer AG, AstraZeneca plc, Johnson & Johnson Inc., Merck & Co., Pfizer Inc., F. Hoffmann-La Roche Ltd, Dr. Reddy’s Laboratories Ltd, among others.
Prominent Therapies include AVASTIN (bevacizumab), TEMODAR/TEMODAL, Vorasidenib, Paxalisib, and others.
The brain cancer market is expected to expand substantially due to rising disease prevalence, increased awareness, and the introduction of multiple-stage pipeline therapies, which are likely to transform the market landscape over the coming years.
Brain Cancer Overview
A brain tumor, also known as an intracranial tumor, is an abnormal growth occurring within the brain, spinal cord, or surrounding protective tissues. These tumors are generally classified as primary or metastatic. Primary tumors are further categorized as low-grade or high-grade. Low-grade tumors usually grow slowly but can progress to high-grade, which are more aggressive. Secondary brain tumors, or brain metastases, are more common in adults than primary tumors.
Brain tumors are often undetected until symptoms appear. Diagnosis usually starts with magnetic resonance imaging (MRI). If a tumor is found, a biopsy or surgery is performed to determine the tumor type by analyzing tissue samples. Blood tests may assist in diagnosing certain tumor types, such as those in the pituitary gland, pineal region, or germ cell tumors. Advanced imaging techniques, including CT scans and MRI, help locate the tumor, while specialized MRI sequences assist surgeons in planning safe removal near critical brain structures. Intraoperative MRI is also employed during surgery to guide biopsies and tumor excision.
Treatment options for brain tumors include surgery, radiation therapy, chemotherapy, and targeted therapy, with the approach depending on tumor size, type, grade, location, whether it has spread, potential side effects, and the patient’s overall health. Low-grade tumors may be treated with surgery alone if fully removable; residual tumor tissue may require radiation or chemotherapy. For high-grade tumors, the standard treatment sequence usually involves surgery followed by radiation therapy and chemotherapy.
Get a Free sample for the Brain Cancer Market Forecast, Size & Share Analysis Report
Brain Cancer Epidemiology
The epidemiology section offers a detailed overview of historical, current, and projected trends in the seven major markets (7MM) from 2020 to 2034. It examines the factors driving both present and future trends by analyzing multiple studies and insights from key opinion leaders. Additionally, the section provides an in-depth assessment of the diagnosed patient population and highlights anticipated epidemiological developments over the forecast period.
Brain Cancer Epidemiology Segmentation:
The Brain Cancer market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:
-
Diagnosed Prevalence of Brain Cancer in Adults
-
Diagnosed Prevalence of Brain Cancer in Pediatrics
-
Diagnosed Prevalence of Brain Cancer by Types
-
Diagnosed Prevalence of Brain Cancer by Location
-
Diagnosed Prevalence of Brain Cancer by Severity
Download the report to understand which factors are driving Brain Cancer epidemiology trends @ Brain Cancer Epidemiology Forecast
Brain Cancer Marketed Drugs
-
AVASTIN (bevacizumab): Genentech
-
TEMODAR/TEMODAL: Merck
Brain Cancer Emerging Drugs
-
Vorasidenib: Servier
-
Paxalisib: Kazia Therapeutics
Brain Cancer Therapies: AVASTIN (bevacizumab), TEMODAR/TEMODAL, Vorasidenib, Paxalisib, and others
Brain Cancer Key Companies: Y-mAbs Therapeutics Inc., Shimadzu Corporation, Bristol-Myers Squibb, Bayer AG, AstraZeneca plc, Johnson & Johnson Inc., Merck & Co., Pfizer Inc., F. Hoffmann-La Roche Ltd, Dr. Reddy’s Laboratories Ltd, and others
Discover more about therapies set to grab major Brain Cancer market share @ Brain Cancer Treatment Landscape
Brain Cancer Market Outlook
Treatment for brain cancer generally involves a multimodal approach, including surgery, chemotherapy, radiation, or stereotactic radiosurgery, often followed by additional adjuvant therapies such as chemotherapy or radiation. Palliative care may also involve these modalities to manage symptoms.
An emerging area of treatment is immunotherapy, which seeks to activate the patient’s immune system to fight and prevent tumor growth. Often described as “vaccine” therapy, this strategy triggers an immune response targeted specifically at the tumor. Immunotherapy approaches may include checkpoint inhibitors and cancer vaccines that use tumor-specific antigens. Ongoing research continues to investigate the potential of immunotherapy, along with other innovative strategies such as gene therapies and oncolytic virus treatments (utilizing viruses like polio, adenovirus, or herpes) to control tumor progression.
Numerous companies are actively developing brain cancer therapies. With the FDA approval of OJEMDA, it now competes with Novartis’ TAFINLAR-MEKINIST combination, approved last year for pediatric low-grade gliomas (pLGG) with BRAF V600 mutations. Leading pharmaceutical companies—including Genentech, Daiichi Sankyo, Bristol Myers Squibb, Bayer, Roche, AstraZeneca, Pfizer, and others—are advancing mid- and late-stage clinical trials for brain cancer treatments, positioning them for substantial market opportunities upon regulatory approval.
Scope of the Brain Cancer Market Report
-
Study Period: 2020–2034
-
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
-
Key Brain Cancer Companies: Y-mAbs Therapeutics Inc., Shimadzu Corporation, Bristol-Myers Squibb, Bayer AG, AstraZeneca plc, Johnson & Johnson Inc., Merck & Co., Pfizer Inc., F. Hoffmann-La Roche Ltd, Dr. Reddy’s Laboratories Ltd, and others
-
Key Brain Cancer Therapies: AVASTIN (bevacizumab), TEMODAR/TEMODAL, Vorasidenib, Paxalisib, and others
-
Brain Cancer Therapeutic Assessment: Brain Cancer current marketed and Brain Cancer emerging therapies
-
Brain Cancer Market Dynamics: Brain Cancer market drivers and Brain Cancer market barriers
-
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
-
Brain Cancer Unmet Needs, KOL’s views, Analyst’s views, Brain Cancer Market Access and Reimbursement
To know more about Brain Cancer companies working in the treatment market, visit @ Brain Cancer Clinical Trials and Therapeutic Assessment
Table of Contents
1. Brain Cancer Market Report Introduction
2. Executive Summary for Brain Cancer
3. SWOT analysis of Brain Cancer
4. Brain Cancer Patient Share (%) Overview at a Glance
5. Brain Cancer Market Overview at a Glance
6. Brain Cancer Disease Background and Overview
7. Brain Cancer Epidemiology and Patient Population
8. Country-Specific Patient Population of Brain Cancer
9. Brain Cancer Current Treatment and Medical Practices
10. Brain Cancer Unmet Needs
11. Brain Cancer Emerging Therapies
12. Brain Cancer Market Outlook
13. Country-Wise Brain Cancer Market Analysis (2020–2034)
14. Brain Cancer Market Access and Reimbursement of Therapies
15. Brain Cancer Market Drivers
16. Brain Cancer Market Barriers
17. Brain Cancer Appendix
18. Brain Cancer Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
Related Reports:
Brain Cancer Pipeline
“Brain Cancer Pipeline Insight, 2024” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Brain Cancer market. A detailed picture of the Brain Cancer pipeline landscape is provided, which includes the disease overview and Brain Cancer treatment guidelines.
Brain Cancer Epidemiology
DelveInsight’s ‘Brain Cancer Epidemiology Forecast to 2034’ report delivers an in-depth understanding of the disease, historical and forecasted Brain Cancer epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/